Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.

Tageja N, Korde N, Kazandjian D, Panch S, Manasanch E, Bhutani M, Kwok M, Mailankody S, Yuan C, Stetler-Stevenson M, Leitman SF, Sportes C, Landgren O.

Bone Marrow Transplant. 2018 Nov;53(11):1445-1449. doi: 10.1038/s41409-018-0170-0. Epub 2018 May 4.

2.

Hepatotoxicity Associated With Vismodegib.

Bedi PS, Rai MP, Tageja N, Laird-Fick H.

BMJ Case Rep. 2018 Feb 8;2018. pii: bcr-2017-222969. doi: 10.1136/bcr-2017-222969.

3.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.

Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O.

Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10.

4.

Host-related immunodeficiency in the development of multiple myeloma.

Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O.

Leuk Lymphoma. 2018 May;59(5):1127-1132. doi: 10.1080/10428194.2017.1361026. Epub 2017 Aug 9.

5.

Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease.

Hofmann JN, Mailankody S, Korde N, Wang Y, Tageja N, Costello R, Zingone A, Hultcrantz M, Pollak MN, Purdue MP, Landgren O.

Obesity (Silver Spring). 2017 Aug;25(8):1317-1320. doi: 10.1002/oby.21894. Epub 2017 Jun 11.

6.

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.

Manasanch EE, de Larrea CF, Zingone A, Steinberg SM, Kwok M, Tageja N, Bhutani M, Kazandjian D, Roschewski M, Wu P, Carter G, Zuchlinski D, Mulquin M, Lamping L, Costello R, Burton D, Gil LA, Figg WD, Maric I, Calvo KR, Yuan C, Stetler-Stevenson M, Korde N, Landgren O.

Leuk Lymphoma. 2017 Mar;58(3):639-645. doi: 10.1080/10428194.2016.1214953. Epub 2016 Aug 9.

7.

Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.

Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tageja N, Mailankody S, Roschewski M, Mulquin M, Carpenter A, Lamping E, Minter AR, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Usmani SZ, Choyke PL, Kurdziel K, Landgren O.

Leuk Lymphoma. 2016 May;57(5):1114-21. doi: 10.3109/10428194.2015.1090572. Epub 2016 Apr 7.

8.

Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines.

Tageja N, Groninger H.

Postgrad Med J. 2016 Jan;92(1083):34-40. doi: 10.1136/postgradmedj-2014-132969. Epub 2015 Nov 11. Review.

PMID:
26561590
9.

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O.

JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.

10.

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.

Mossoba ME, Halverson DC, Kurlander R, Schuver BB, Carpenter A, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche J, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Khuu H, Sabatini M, Stroncek D, Levine BL, June CH, Mariotti J, Rixe O, Fojo AT, Bishop MR, Gress RE, Fowler DH.

Clin Cancer Res. 2015 Oct 1;21(19):4312-20. doi: 10.1158/1078-0432.CCR-15-0340. Epub 2015 Jun 12.

11.

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.

Manasanch EE, Korde N, Mailankody S, Tageja N, Bhutani M, Roschewski M, Landgren O.

Haematologica. 2014 Dec;99(12):1769-71. doi: 10.3324/haematol.2014.107516. No abstract available.

12.

Brain metastasis in patients with adrenocortical carcinoma: a clinical series.

Burotto M, Tageja N, Rosenberg A, Mahalingam S, Quezado M, Velarde M, Edgerly M, Fojo T.

J Clin Endocrinol Metab. 2015 Feb;100(2):331-6. doi: 10.1210/jc.2014-2650. Epub 2014 Nov 20.

13.

Chemotherapy-induced nausea and vomiting #285.

Tageja N, Groninger H.

J Palliat Med. 2014 Dec;17(12):1400-2. doi: 10.1089/jpm.2014.9392. No abstract available.

14.

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.

Manasanch EE, Salem DA, Yuan CM, Tageja N, Bhutani M, Kwok M, Kazandjian D, Carter G, Steinberg SM, Zuchlinski D, Mulquin M, Calvo K, Maric I, Roschewski M, Korde N, Braylan R, Landgren O, Stetler-Stevenson M.

Leuk Lymphoma. 2015 May;56(5):1416-24. doi: 10.3109/10428194.2014.955020. Epub 2014 Oct 30.

15.

Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.

Zingone A, Wang W, Corrigan-Cummins M, Wu SP, Plyler R, Korde N, Kwok M, Manasanch EE, Tageja N, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Roschewski M, Zhang Y, Roccaro AM, Ghobrial IM, Calvo KR, Landgren O.

Cytokine. 2014 Oct;69(2):294-7. doi: 10.1016/j.cyto.2014.05.017. Epub 2014 Jul 17.

16.

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

Korde N, Carlsten M, Lee MJ, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.

Haematologica. 2014 Jun;99(6):e81-3. doi: 10.3324/haematol.2013.103085. Epub 2014 Mar 21. No abstract available.

17.

MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.

Landgren O, Tageja N.

Leukemia. 2014 Sep;28(9):1799-803. doi: 10.1038/leu.2014.88. Epub 2014 Feb 27. Review.

PMID:
24573383
18.

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M.

Leuk Res. 2014 Mar;38(3):371-6. doi: 10.1016/j.leukres.2013.12.007. Epub 2013 Dec 11.

19.

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.

Manasanch EE, Korde N, Zingone A, Tageja N, Fernandez de Larrea C, Bhutani M, Wu P, Roschewski M, Landgren O.

Leuk Lymphoma. 2014 Aug;55(8):1707-14. doi: 10.3109/10428194.2013.828351. Epub 2014 Jan 24. Review.

PMID:
24261677
20.

Smoldering multiple myeloma: present position and potential promises.

Tageja N, Manasanch EE, Korde N, Kwok M, Mailankody S, Bhutani M, Roschewski M, Landgren O.

Eur J Haematol. 2014 Jan;92(1):1-12. doi: 10.1111/ejh.12205. Epub 2013 Nov 26. Review.

PMID:
24112232
21.

Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma.

Manasanch EE, Braylan R, Stetler-Stevenson M, Yuan C, Gounden V, Korde N, Tageja N, Bhutani M, Calvo K, Maric I, Roschewski M, Staudt LM, Landgren O.

Leuk Lymphoma. 2014 Jun;55(6):1402-3. doi: 10.3109/10428194.2013.831091. Epub 2013 Dec 2. No abstract available.

22.

Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.

Bhutani D, Zonder J, Valent J, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Lum L, Ratanatharathorn V, Uberti J, Abidi MH.

Support Care Cancer. 2013 Sep;21(9):2437-42. doi: 10.1007/s00520-013-1808-5. Epub 2013 Apr 17.

23.

A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.

Abidi MH, Agarwal R, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Ratanatharathorn V, Zonder J, Uberti J.

Biol Blood Marrow Transplant. 2013 Jan;19(1):56-61. doi: 10.1016/j.bbmt.2012.08.003. Epub 2012 Aug 11.

24.

Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.

Abidi MH, Tageja N, Ayash L, Abrams J, Ratanatharathorn V, Al-Kadhimi Z, Lum L, Cronin S, Ventimiglia M, Uberti J.

Support Care Cancer. 2012 Oct;20(10):2363-9. doi: 10.1007/s00520-011-1341-3. Epub 2011 Dec 23.

25.

Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma.

Tageja N.

Clin Med Insights Oncol. 2011;5:145-56. doi: 10.4137/CMO.S6085. Epub 2011 May 18.

26.

Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia.

Tageja N, Giorgadze T, Zonder J.

Intern Med J. 2011 Mar;41(3):286-8. doi: 10.1111/j.1445-5994.2011.02426.x.

PMID:
21426467
27.

Lenalidomide - current understanding of mechanistic properties.

Tageja N.

Anticancer Agents Med Chem. 2011 Mar;11(3):315-26. Review.

PMID:
21426296
28.

Hepatocellular carcinoma--does early diagnosis really lead to better outcome?

Tageja N.

Eur J Intern Med. 2011 Apr;22(2):211; author reply 212. doi: 10.1016/j.ejim.2010.05.001. No abstract available.

PMID:
21402256
29.

Chemotherapy for hormone-refractory prostate cancer: a physician's dilemma.

Tageja N.

Intern Med J. 2010 Dec;40(12):864-5. doi: 10.1111/j.1445-5994.2010.02350.x. No abstract available.

PMID:
21199229
30.

Residents' perceptions of their competence in end-of-life care: suggestions for further research.

Tageja N.

Acad Med. 2011 Jan;86(1):4-5; author reply 5. doi: 10.1097/ACM.0b013e3181ff6644. No abstract available.

PMID:
21191196
31.

Bridging the translation gap - new hopes, new challenges.

Tageja N.

Fundam Clin Pharmacol. 2011 Apr;25(2):163-71. doi: 10.1111/j.1472-8206.2010.00903.x. Epub 2010 Dec 13. Review.

PMID:
21155875
32.

We can reduce US health care costs: a resident's perspective.

Tageja N.

Am J Med. 2010 Oct;123(10):e27; author reply e29. doi: 10.1016/j.amjmed.2010.04.031. No abstract available.

PMID:
20920679
33.

POEMS syndrome, congestive heart failure and thalidomide -food for thought.

Tageja N.

Intern Med. 2010;49(17):1919; author reply 1921. Epub 2010 Sep 1. No abstract available.

34.

Multidrug-resistant tuberculosis in India.

Tageja N, Sharma V.

Lancet. 2010 Aug 28;376(9742):682-3. doi: 10.1016/S0140-6736(10)61330-X. No abstract available.

PMID:
20801396
35.

Standing at the crossroads-will the increments in resident clinic sessions help?

Tageja N.

South Med J. 2010 Jun;103(6):593. doi: 10.1097/SMJ.0b013e3181d9d2e2. No abstract available.

PMID:
20710155
36.

Health screening services--ready for a "virtual" joyride?

Tageja N.

Prev Med. 2010 Nov;51(5):433. doi: 10.1016/j.ypmed.2010.07.020. Epub 2010 Aug 5. No abstract available.

PMID:
20691722
37.

Prognostic indicators for Ewing's sarcoma.

Tageja N.

Lancet. 2010 Jul 24;376(9737):232. doi: 10.1016/S0140-6736(10)61141-5. No abstract available.

PMID:
20656121
38.

Resident teaching--from bedside to open corridors and closed rooms.

Tageja N.

Intern Emerg Med. 2011 Jun;6(3):277-8. doi: 10.1007/s11739-010-0421-6. Epub 2010 Jul 6. No abstract available.

PMID:
20607452
39.

Relationship between anemia and cognitive functions in the geriatric population.

Tageja N.

Eur J Intern Med. 2010 Aug;21(4):e26. doi: 10.1016/j.ejim.2010.05.005. Epub 2010 Jun 8. No abstract available.

PMID:
20603029
40.

Precursor T cell acute lymphoblastic lymphoma presenting as bilateral facial nerve palsy.

Tageja N, Valent J, Bentley G, Zonder J.

Chemotherapy. 2010;56(3):258-60. doi: 10.1159/000316847. Epub 2010 Jun 16. No abstract available.

PMID:
20551643
41.

Plasma cell leukemia presenting as organizing pneumonia refractory to high-dose steroid therapy.

Tageja N, Nagi J, Valent J, Zonder J.

South Med J. 2010 Jul;103(7):706-10. doi: 10.1097/SMJ.0b013e3181e206da.

PMID:
20531051
42.

Wernicke's encephalopathy after laparoscopic Roux-en-Y gastric bypass: a misdiagnosed complication.

Tageja N.

Obes Surg. 2010 Sep;20(9):1327; author reply 1328. doi: 10.1007/s11695-010-0208-x. No abstract available.

PMID:
20526863
43.

Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience.

Hammad N, Heilbrun LK, Gupta S, Tageja N, Philip PA, Shields AF, Smith D, El-Rayes BF.

Am J Clin Oncol. 2011 Apr;34(2):135-9. doi: 10.1097/COC.0b013e3181dbb710.

44.

Bendamustine: something old, something new.

Tageja N, Nagi J.

Cancer Chemother Pharmacol. 2010 Aug;66(3):413-23. doi: 10.1007/s00280-010-1317-x. Epub 2010 Apr 8. Review.

PMID:
20376452
45.

Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report.

Tageja N, Mohammad M, Bentley G, Bishop C.

Case Rep Med. 2010;2010:729790. doi: 10.1155/2010/729790. Epub 2010 Mar 24.

46.

Myonecrosis in sickle cell anemia-overlooked and underdiagnosed.

Tageja N, Racovan M, Valent J, Zonder J.

Case Rep Med. 2010;2010:659031. doi: 10.1155/2010/659031. Epub 2010 Mar 11.

47.

Positive pregnancy tests in a postmenopausal woman due to beta-human chorionic gonadotropin production by multiple myeloma.

Tageja N, Valent J, Giorgadze T, Bentley G, Zonder J.

Am J Med Sci. 2010 Feb;339(2):182-4. doi: 10.1097/MAJ.0b013e3181bccedb.

PMID:
20145436
48.

Treatment of relapsed acute promyelocytic leukemia with gemtuzumab ozogamicin and all-trans retinoic acid.

Tageja N, Valent J, Zonder J.

J Chemother. 2009 Dec;21(6):705-6. No abstract available.

PMID:
20071299
49.

Upper gastrointestinal bleeding in a patient with a history of peptic ulcer disease: don't presume the diagnosis.

Tageja N, Sethi S, Rathod A.

South Med J. 2010 Feb;103(2):181-2. doi: 10.1097/SMJ.0b013e3181c98de6. No abstract available.

PMID:
20065905
50.

New targets for the treatment of follicular lymphoma.

Tageja N, Padheye S, Dandawate P, Al-Katib A, Mohammad RM.

J Hematol Oncol. 2009 Dec 23;2:50. doi: 10.1186/1756-8722-2-50. Review.

Supplemental Content

Loading ...
Support Center